US safety data show that elinzanetant caused few adverse events and no new liver-related concerns in women, James Simon, MD, explains.
James Simon, MD
Advertisement
Articles by James Simon, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
IEHP CEO Weighs in: Who Pays the Price When Millions Lose Medicaid Coverage?
2
FDA Approves Elinzanetant, a Hormone-Free Option for Hot Flashes in Menopause
3
FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma
4
Revumenib Granted FDA Approval for R/R NPM1-Mutated AML
5
